# Niagen Bioscience, Inc.: Form 8-K, filed Nov 8, 2023

- Company: [Niagen Bioscience, Inc.](/companies/nage.md) (CIK 1386570)
- Form: 8-K
- Filed: 2023-11-08
- Accepted by EDGAR: Nov 8, 2023, 16:02 ET
- Period: 2023-11-08
- Accession: 0001628280-23-037816
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1386570/000162828023037816/cdxc-20231108.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1386570/000162828023037816/

## Items reported

- Item 2.02: Results of operations
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1386570/000162828023037816/cdxc-20231108.htm

Filed Nov 8, 2023.
Source: SEC EDGAR, the filing index for accession 0001628280-23-037816. Last ingested by Listed: Oct 24, 2026, 15:12 ET. No prices; not investment advice.